|
Market Closed -
Nasdaq
23:00:00 19/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 10.07 USD | +3.81% |
|
-4.91% | +29.10% |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,573 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 56.69% | - | - |
| Enterprise Value (EV) | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,573 | 2,573 | 2,573 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 56.69% | 0% | 0% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -4.39x | 15.2x | 11.9x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -8.24x | -221x | 5.46x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.4x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.66x | 3.49x | 3.07x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.66x | 3.49x | 3.07x |
| EV / EBITDA | -0x | -0x | -0x | -0x | 0x | -5.17x | 12.6x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -5.06x | 10.4x | 7.98x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -370x | 9.34x | 6.47x |
| FCF Yield | -5.8% | -7.63% | -7.93% | -3.41% | 21% | -0.27% | 10.7% | 15.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.296 | 0.6647 | 0.8435 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 702.2 | 737.3 | 837.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -497.8 | 204.5 | - |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 322.4 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -578.8 | 184.4 | 253.9 |
| Net Debt | -368.3 | - | 426.7 | 507.7 | - | - | - | - |
| Reference price 2 | 13.85 | 11.48 | 5.99 | 7.52 | 7.80 | 10.07 | 10.07 | 10.07 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 255,535 | - | - |
| Announcement Date | 2/23/22 A | 2/21/23 A | 2/26/24 A | 2/24/25 A | 2/26/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.39x | - | - | -.--% | 2.57B | |
| 21.6x | 7.56x | 15.41x | 1.37% | 72.21B | |
| 36.46x | 9.42x | 28.89x | 0.04% | 63.98B | |
| -82.59x | 15.45x | -74.5x | -.--% | 28.53B | |
| 31.75x | 6.24x | 16.52x | -.--% | 25.07B | |
| -17.57x | 7.2x | -9.35x | -.--% | 28.42B | |
| 27.22x | 5.11x | 17.13x | -.--% | 20.04B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.19B | |
| 7705.33x | 40.58x | -1416.2x | -.--% | 15.96B | |
| 16.82x | 4.99x | 11.65x | -.--% | 13.48B | |
| Average | 778.75x | 12.90x | -152.31x | 0.17% | 28.85B | |
| Weighted average by Cap. | 438.63x | 10.93x | -71.34x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
